GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.
暂无分享,去创建一个
B. Monk | S. Lheureux | I. Vergote | I. Lowy | D. Rischin | A. Santin | D. Chase | A. Oaknin | K. Tewari | M. Fury | S. Gaillard | E. Alvarez | M. Mathias | M. Feng